{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:12:41Z","timestamp":1793261561566,"version":"4.5.0"},"reference-count":26,"publisher":"George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures","issue":"4","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Introduction<\/jats:bold>\n                    : Congenital heart diseases (CHD) have been reported to be responsible for 30 to 50% of infant mortality caused by congenital disabilities. In critical cases, survival of newborns with CHD depends on the patency of the ductus arteriosus (PDA), for maintaining the systemic or pulmonary circulation. The aim of the study was to assess the efficacy and side effects of PGE (prostaglandin E) administration in newborns with critical congenital heart disease requiring maintenance of the ductus arteriosus.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Material and method<\/jats:bold>\n                    : All clinical and paraclinical data of 66 infants admitted to one referral tertiary level academic center and treated with Alprostadil were analyzed. Patients were divided into three groups: Group 1: PDA dependent pulmonary circulation (n=11) Group 2: PDA dependent systemic circulation (n=31) Group 3: PDA depending mixed circulation (n=24)\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    : The mean age of starting PGE1 treatment was 2.06 days, 1.91 (+\/\u22121.44) days for PDA depending pulmonary flow, 2.39 (+\/\u22121.62) days for PDA depending systemic flow and 1.71 (+\/1.12) for PDA depending mixing circulation. PEG1 initiation was commenced 48 hours after admission for 72%, between 48-72 hours for 6%, and after 72 to 120 hours for 21% of newborns detected with PDA dependent circulation. Before PEG1 initiation the mean initial SpO2 was 77.89 (+\/\u2212 9.2)% and mean initial oxygen pressure (PaO2) was 26.96(+\/\u22126.45) mmHg. At the point when stable wide open PDA was achieved their mean SpO2increased to 89.73 (+\/\u22128.4)%, and PaO2 rose to 49 (+\/\u22127.2) mmHg. During PGE1 treatment, eleven infants (16.7%) had apnea attacks, five children (7.5%) had convulsions, 33 (50%) had fever, 47 (71.2%) had leukocytosis, 52 (78.8%) had edema, 25.8% had gastrointestinal intolerance, 45.5% had hypokalemia, and 63.6% had irritability.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions<\/jats:bold>\n                    : For those infants with severe cyanosis or shock caused by PDA dependent heart lesions, the initiation and maintenance of PGE1 infusion is imperative. The side effects of this beneficial therapy were transient and treatable.\n                  <\/jats:p>","DOI":"10.1515\/jccm-2016-0031","type":"journal-article","created":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T05:04:35Z","timestamp":1478667875000},"page":"185-191","source":"Crossref","is-referenced-by-count":26,"title":["Congenital Heart Disease Requiring Maintenance of Ductus Arteriosus in Critically Ill Newborns Admitted at A Tertiary Neonatal Intensive Care Unit"],"prefix":"10.62838","volume":"2","author":[{"given":"Manuela","family":"Cucerea","sequence":"first","affiliation":[{"name":"University of Medicine and Pharmacy Tirgu Mure\u0219, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Simon","sequence":"additional","affiliation":[{"name":"University of Medicine and Pharmacy Tirgu Mure\u0219, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Moldovan","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Disease and Transplant Tirgu Mure\u0219, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Ungureanu","sequence":"additional","affiliation":[{"name":"Department of Neonatal Intensive Care, County Clinical Emergency Hospital Tirgu Mure\u015f, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"Marian","sequence":"additional","affiliation":[{"name":"University of Medicine and Pharmacy Tirgu Mure\u0219, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Suciu","sequence":"additional","affiliation":[{"name":"University of Medicine and Pharmacy Tirgu Mure\u0219, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"49540","published-online":{"date-parts":[[2016,11,8]]},"reference":[{"key":"2021040611521932066_j_jccm-2016-0031_ref_001_w2aab2b8ab1b7b1ab1ab1Aa","doi-asserted-by":"crossref","unstructured":"1. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39:1890\u2013900.","DOI":"10.1016\/S0735-1097(02)01886-7"},{"key":"2021040611521932066_j_jccm-2016-0031_ref_002_w2aab2b8ab1b7b1ab1ab2Aa","doi-asserted-by":"crossref","unstructured":"2. Oster ME, Lee KA, Honein MA, Riehle-Colarusso T, Shin M, Correa A. Temporal trends in survival among infants with critical congenital heart defects. Pediatrics. 2013;131:e1502-8. doi: 10.1542\/peds.2012-3435.","DOI":"10.1542\/peds.2012-3435"},{"key":"2021040611521932066_j_jccm-2016-0031_ref_003_w2aab2b8ab1b7b1ab1ab3Aa","doi-asserted-by":"crossref","unstructured":"3. Reller MD, Strickland MJ, Riehle-Colarusso T, Mahle WT, Correa A. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr. 2008;153:807-13. doi: 10.1016\/j.jpeds.2008.05.059","DOI":"10.1016\/j.jpeds.2008.05.059"},{"key":"2021040611521932066_j_jccm-2016-0031_ref_004_w2aab2b8ab1b7b1ab1ab4Aa","doi-asserted-by":"crossref","unstructured":"4. Yun SW. Congenital heart disease in the newborn requiring early intervention. Korean J Pediatr. 2011;54:183\u201391. doi: 10.3345\/kjp.2011.54.5.183","DOI":"10.3345\/kjp.2011.54.5.183"},{"key":"2021040611521932066_j_jccm-2016-0031_ref_005_w2aab2b8ab1b7b1ab1ab5Aa","doi-asserted-by":"crossref","unstructured":"5. Olney RS, Ailes EC, Sontag MK. Detection of critical congenital heart defects: Review of contributions from prenatal and newborn screening. Semin Perinatol. 2015;39:230-7. doi: 10.1053\/j.semperi.2015.03.007.","DOI":"10.1053\/j.semperi.2015.03.007"},{"key":"2021040611521932066_j_jccm-2016-0031_ref_006_w2aab2b8ab1b7b1ab1ab6Aa","doi-asserted-by":"crossref","unstructured":"6. American Institute of Ultrasound in Medicine. AIUM practice guideline for the performance of an antepartum obstetric ultrasound examination. J Ultrasound Med. 2003;22:1116\u201325.","DOI":"10.7863\/jum.2003.22.10.1116"},{"key":"2021040611521932066_j_jccm-2016-0031_ref_007_w2aab2b8ab1b7b1ab1ab7Aa","doi-asserted-by":"crossref","unstructured":"7. AIUM practice guideline for the performance of obstetric ultrasound examinations. J Ultrasound Med. 2010;29:157\u201366.","DOI":"10.7863\/jum.2010.29.1.157"},{"key":"2021040611521932066_j_jccm-2016-0031_ref_008_w2aab2b8ab1b7b1ab1ab8Aa","doi-asserted-by":"crossref","unstructured":"8. Momma K, Uemura S, Nishihara S, Ota Y. Dilatation of the ductus arteriosus by prostaglandins and prostaglandin\u2019s precursors. Pediatr Res. 1980;14:1074-7. DOI: 10.1203\/00006450-198009000-00011","DOI":"10.1203\/00006450-198009000-00011"},{"key":"2021040611521932066_j_jccm-2016-0031_ref_009_w2aab2b8ab1b7b1ab1ab9Aa","doi-asserted-by":"crossref","unstructured":"9. Heymann MA, Rudolph AM. Ductus arteriosus dilatation by prostaglandin E1 in infants with pulmonary atresia. Pediatrics. 1977;59:325-9.","DOI":"10.1542\/peds.59.3.325"},{"key":"2021040611521932066_j_jccm-2016-0031_ref_010_w2aab2b8ab1b7b1ab1ac10Aa","doi-asserted-by":"crossref","unstructured":"10. Benson LN, Olley PM, Patel RG, Coceani F, Rowe RD. Role of prostaglandin E1 infusion in the management of transposition of the great arteries. Am J Cardiol.1979;44:691\u20136.","DOI":"10.1016\/0002-9149(79)90289-3"},{"key":"2021040611521932066_j_jccm-2016-0031_ref_011_w2aab2b8ab1b7b1ab1ac11Aa","doi-asserted-by":"crossref","unstructured":"11. Hundalani SG, Kulkarni M, Fernandes CJ, Cabrera AG, Shivanna B, Pammi M. Prostaglandin E1 for maintaining ductal patency in neonates with ductus-dependent cardiac lesions (Protocol). Cochrane Database of Systematic Reviews. 2014;12:CD011417. DOI: 10.1002\/14651858.CD011417.","DOI":"10.1002\/14651858.CD011417"},{"key":"2021040611521932066_j_jccm-2016-0031_ref_012_w2aab2b8ab1b7b1ab1ac12Aa","doi-asserted-by":"crossref","unstructured":"12. Kobayashi T, Narumiya S. Function of prostanoid receptors: studies on knockout mice. Prostaglandins Other Lipid Mediat. 2002;68-69:557-73.","DOI":"10.1016\/S0090-6980(02)00055-2"},{"key":"2021040611521932066_j_jccm-2016-0031_ref_013_w2aab2b8ab1b7b1ab1ac13Aa","doi-asserted-by":"crossref","unstructured":"13. Reese J, Veldman A, Shah L, Vucovich M, Cotton RB. Inadvertent relaxation of the ductus arteriosus by pharmacologic agents that are commonly used in the neonatal period. Semin Perinatol. 2010;34:222-30. doi: 10.1053\/j.semperi.2010.02.007.","DOI":"10.1053\/j.semperi.2010.02.007"},{"key":"2021040611521932066_j_jccm-2016-0031_ref_014_w2aab2b8ab1b7b1ab1ac14Aa","doi-asserted-by":"crossref","unstructured":"14. Buck ML. Prostaglandin E1 treatment of congenital heart disease: use prior to neonatal transport. DICP. 1991;25:408-9.","DOI":"10.1177\/106002809102500413"},{"key":"2021040611521932066_j_jccm-2016-0031_ref_015_w2aab2b8ab1b7b1ab1ac15Aa","doi-asserted-by":"crossref","unstructured":"15. Moldovan E, Cucerea M. Drug Closure of a Patent Ductus Arteriosus in An Extremely Low Birth Weight Premature Newborn. A Case Report. J Crit Care Med. 2015;1:28-32. DOI: 10.1515\/jccm-2015-0006","DOI":"10.1515\/jccm-2015-0006"},{"key":"2021040611521932066_j_jccm-2016-0031_ref_016_w2aab2b8ab1b7b1ab1ac16Aa","doi-asserted-by":"crossref","unstructured":"16. Dolbec K. Congenital heart disease. Emerg Med Clin North Am. 2011;29:811-27. doi: 10.1016\/j.emc.2011.08.005.","DOI":"10.1016\/j.emc.2011.08.005"},{"key":"2021040611521932066_j_jccm-2016-0031_ref_017_w2aab2b8ab1b7b1ab1ac17Aa","unstructured":"17. Yaffe SJ, Aranda JV. Neonatal and Pediatric Pharmacology 4e: Therapeutic Principles In Practice. Lippincott Williams & Wilkins, Philadelphia, PA. 2011."},{"key":"2021040611521932066_j_jccm-2016-0031_ref_018_w2aab2b8ab1b7b1ab1ac18Aa","doi-asserted-by":"crossref","unstructured":"18. Toganel R. Critical Congenital Heart Diseases as Lifethreatening Conditions in the Emergency Room. Journal of Cardiovascular Emergencies. 2016;2:7-10. DOI: 10.1515\/jce-2016-0002.","DOI":"10.1515\/jce-2016-0002"},{"key":"2021040611521932066_j_jccm-2016-0031_ref_019_w2aab2b8ab1b7b1ab1ac19Aa","doi-asserted-by":"crossref","unstructured":"19. Chamberlin M, Lozynski J. To go against nature: manipulating the neonatal ductusarteriosus with prostaglandin. Newborn and Infant Nursing Reviews. 2006;6:158-62. DOI: 10.1053\/j.nainr.2006.05.001.","DOI":"10.1053\/j.nainr.2006.05.001"},{"key":"2021040611521932066_j_jccm-2016-0031_ref_020_w2aab2b8ab1b7b1ab1ac20Aa","doi-asserted-by":"crossref","unstructured":"20. Elliott RB, Starling MB, Neutze JM. Medical manipulation of the ductus arteriosus. Lancet.1975;1:140e2.","DOI":"10.1016\/S0140-6736(75)91432-4"},{"key":"2021040611521932066_j_jccm-2016-0031_ref_021_w2aab2b8ab1b7b1ab1ac21Aa","unstructured":"21. Nelson textbook of paediatrics. Arch Dis Child 1983;58:942."},{"key":"2021040611521932066_j_jccm-2016-0031_ref_022_w2aab2b8ab1b7b1ab1ac22Aa","doi-asserted-by":"crossref","unstructured":"22. Olley PM, Coceani F, Bodach E. E-type prostaglandins: a new emergency therapy for certain cyanotic congenital heart malformations. Circulation.1976;53:728 e31.http:\/\/dx.doi.org\/10.1161\/01.CIR.53.4.728","DOI":"10.1161\/01.CIR.53.4.728"},{"key":"2021040611521932066_j_jccm-2016-0031_ref_023_w2aab2b8ab1b7b1ab1ac23Aa","doi-asserted-by":"crossref","unstructured":"23. Heymann MA, Rudolph AM. Ductus arteriosus dilatation by prostaglandin E1 in infants with pulmonary atresia. Pediatrics.1977;59:325e9.","DOI":"10.1542\/peds.59.3.325"},{"key":"2021040611521932066_j_jccm-2016-0031_ref_024_w2aab2b8ab1b7b1ab1ac24Aa","doi-asserted-by":"crossref","unstructured":"24. Huang FK, Lin CC, Huang TC, et al. Reappraisal of the prostaglandin E1 dose for early newborns with patent ductus arteriosus-dependent pulmonary circulation. Pediatr Neonatol. 2013;54:102-6. doi: 10.1016\/j.pedneo.2012.10.007.","DOI":"10.1016\/j.pedneo.2012.10.007"},{"key":"2021040611521932066_j_jccm-2016-0031_ref_025_w2aab2b8ab1b7b1ab1ac25Aa","doi-asserted-by":"crossref","unstructured":"25. Talosi G, Katona M, T\u00fari S. Side-effects of long-term prostaglandin E(1) treatment in neonates. Pediatr Int. 2007;49:335-40. DOI: 10.1111\/j.1442-200X.2007.02380.x","DOI":"10.1111\/j.1442-200X.2007.02380.x"},{"key":"2021040611521932066_j_jccm-2016-0031_ref_026_w2aab2b8ab1b7b1ab1ac26Aa","doi-asserted-by":"crossref","unstructured":"26. Middleton P, Kelly AM, Brown J, Robertson M. Agreement between arterial and central venous values for pH, bicarbonate, base excess, and lactate. Emerg Med J. 2006;23:622-4. DOI: 10.1136\/emj.2006.035915","DOI":"10.1136\/emj.2006.035915"}],"container-title":["The Journal of Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/content.sciendo.com\/view\/journals\/jccm\/2\/4\/article-p185.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciendo.com\/article\/10.1515\/jccm-2016-0031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:10:58Z","timestamp":1777288258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciendo.com\/article\/10.1515\/jccm-2016-0031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,1]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,11,8]]},"published-print":{"date-parts":[[2016,10,1]]}},"alternative-id":["10.1515\/jccm-2016-0031"],"URL":"https:\/\/doi.org\/10.1515\/jccm-2016-0031","relation":{},"ISSN":["2393-1817"],"issn-type":[{"value":"2393-1817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,1]]}}}